Updates on the Management of Immunotherapy-Related Toxicities

With the increased use of immune checkpoint inhibition (ICI) comes an increase in number patients being treated for immune-related adverse events (irAEs). At NCCN 2023 Annual Conference, presenters discussed 3 different types irAEs, namely immune-mediated pneumonitis, major cardiac including myocarditis and myositis/myasthenia gravis overlap syndrome, oral toxicities mucositis sicca syndrome. They emphasized importance considering comorbidities infectious causes when treating pneumonitis. In context during ICI therapy, presentation highlighted need early detection vigilance recognizing insidious, nonspecific symptoms, particularly cases involving with Finally, increasing recognition was discussed, addition to timely intervention prevent long-term morbidity.